ArticleJTCVS techniques2025
Successful use of bivalirudin in neonates for postoperative aortopulmonary shunt thrombosis prevention.
Article in JTCVS techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Standardized Perioperative Thrombosis Prevention in Neonatal Modified Blalock-Taussig Shunt Surgery: An Algorithm-Based Single-Center Case Series.Children (Basel, Switzerland) · 2026Article
- Effects of bivalirudin on instant blood-mediated inflammatory reaction after intraportal islet transplantation.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aim to describe the successful use of bivalirudin for immediate postoperative aortopulmonary shunt thrombosis prevention. This article also describes the details of an institutional protocol for postoperative aortopulmonary shunt thrombosis prevention. In addition, we demonstrate the safe and effective use of low-molecular-weight heparin and aspirin for interstage thrombosis prevention. Methods: Retrospective cohort study of neonates (excluding infants younger than age 1 day and older than age 28 days) undergoing stage 1 single-ventricle palliation with either a modified Blalock Taussig Thomas or central shunt over a 2-year period. Results: Eighteen consecutive neonates were studied, 11 patients after modified Blalock Taussig Thomas shunt and 7 after central shunt. All patients were initiated on bivalirudin infusion of 0.2 mg/kg/h. Patients remained within the target partial thromboplastin time range of 50 to 70 seconds a median of 97% of the time. None of the 18 patients had shunt thrombosis during the first 21 days after surgery. There were 2 patients who experienced late shunt thrombosis (61 and 27 days), prompting the addition of low-molecular-weight heparin to aspirin after transition from bivalirudin. With low-molecular-weight heparin and aspirin, there were no further shunt thromboses and all patients survived to second-stage surgery. Conclusions: Bivalirudin is a safe and effective alternative to unfractionated heparin for immediate postoperative aortopulmonary shunt thrombosis prevention. Transition to low-molecular-weight heparin and aspirin resulted in effective and safe thrombosis prevention through the second-stage surgery. This regimen resulted in no bleeding complications in this cohort of 18 infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.